ClinicalTrials.gg
Not yet recruitingNCT06633783Updated Oct 9, 2024

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

A Phase 3 interventional study of Semaglutide and Semaglutide in Obesity, sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,. Not yet recruiting at 14 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd., · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Planned enrollment
26th of 143
370 · median 100
Started
2024
with 18 others
Phase 3
42 of 143
10 open now
Primary completion
2026-05
later than 9 of 76 live
Registered
87th of 143
by date

Among the 143 studies testing semaglutide in Obesity, this one is the 26th largest by planned enrollment, is one of 19 that started in 2024, is one of 42 in phase 3, reaches primary completion later than 9 of the 76 other live ones, and was the 87th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.

Read the detailed description

The study will involve participants engaging in discussions with study staff regarding healthy dietary choices, strategies for increasing physical activity, and additional methods for achieving weight loss, alongside the administration of the study medication. Participants will be randomly assigned to receive either semaglutide injection or Wegovy®. The study medication will be administered via a weekly subcutaneous injection using a fine needle in the abdominal skinfold. The duration of the study will be approximately 2 years, during which participants will attend 13 clinic visits with the study physician.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this trial and sign the form.
  2. Male or female, aged 18-75 years (inclusive) at the time of signing the informed consent form.
  3. (BMI) ≥28.0 kg/m2 at screening. (4)At least one self-reported unsuccessful weight loss history.

Exclusion criteria

Exclusion Criteria:

  • Blood Glucose-Related:

    1. (HbA1c) level ≥6.5% at screening.
    2. History of type 1 or type 2 diabetes.
    3. Received hypoglycemic drug treatment within 90 days prior to screening.
    4. Received GLP-1 receptor agonist treatment within 180 days prior to screening.
  • Obesity-Related:

    (5)Self-reported weight change >5 kg within 90 days prior to screening, regardless of medical history.

    (6)Received any drug treatment for obesity within 90 days prior to screening. (7)Previous or planned surgical or device treatment for obesity during the trial period, except for the following: (1) liposuction and/or abdominal lipolysis performed >1 year prior to screening; (2) gastric banding with the band removed >1 year prior to screening; (3) intragastric balloon placement with the balloon removed >1 year prior to screening.

  • Psychological Health-Related:

    (8)History of severe depression or a Patient Health Questionnaire-9 (PHQ-9) score ≥15 at screening.

    (9)Diagnosed with other severe mental illnesses, including schizophrenia, schizoaffective disorder, paranoid psychosis, bipolar (affective) disorder, epilepsy-induced mental disorder, and mental retardation with mental disorders.

    (10)History of suicidal behavior. (11)Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.

  • General Safety:

    (12) Thyroid diseases: Including a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); or calcitonin (CT) ≥50ng/L at screening; or thyroid-stimulating hormone (TSH) >6.0mIU/L or \<0.4mIU/L at screening; or concurrent hyperthyroidism.

    (13) History of acute or chronic pancreatitis, or blood amylase ≥3× at screening, or triglycerides (TG) ≥5.65 mmol/L (500 mg/dL) at screening.

    (14) (ALT) ≥3×ULN, aspartate aminotransferase (AST) ≥3×ULN, or total (TBiL) ≥3×ULN at screening.

    (15) Serum creatinine level ≥1.5 mg/dL (132μmol/L) in males or ≥1.4 mg/dL (123μmol/L) in females at screening.

    (16) Untreated or poorly controlled hypertension (defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg).

    (17) Severe cardiac history, defined as (NYHA) class III and IV at screening, and/or hospitalization for unstable angina pectoris or within 60 days prior to screening, and/or stroke (except lacunar infarction) or myocardial infarction within 180 days prior to screening.

    (18) Gastrointestinal diseases assessed by the investigator to potentially increase the risk after medication (such as obstructive diseases: pyloric obstruction and intestinal obstruction; or gastrointestinal motility disorders: postoperative gastroparesis, idiopathic gastroparesis; or severe active ulcers, etc.).

    (19) Known or suspected allergy to any component of semaglutide injection or other GLP-1 receptor agonists.

    (20) Use of drugs that may cause significant weight gain within 90 days prior to screening or expected during the trial, including systemic therapy for more than 1 week; tricyclic antidepressants (such as amitriptyline, imipramine, clomipramine, doxepin); antipsychotic or antiepileptic drugs (such as mirtazapine, paroxetine, phenelzine, chlorpromazine hydrochloride, chlorpromazine, olanzapine, valproic acid and its derivatives, lithium preparations, methimazole).

    (21) Obesity caused by other endocrine diseases, including hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing\'s syndrome, insulinoma, acromegaly, pseudohypoparathyroidism, and hypogonadism.

    (22) Known subjects planned for hospitalization for any surgical treatment during the trial at screening.

    (23) Participated in other clinical trials and used drugs within 90 days prior to screening.

    (24) History of drug abuse (including drug addiction) and/or alcohol dependence within 180 days prior to screening.

    (25) Diagnosed with malignant tumors within 5 years prior to screening (except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery).

    (26) Pregnant or lactating women, females or males with reproductive plans during the trial period or unwilling to use effective methods.

    (27) Subjects who, in the investigator\'s judgment, have any disease or other conditions that may endanger their safety or affect their compliance with the protocol, making them unsuitable for participation in this study.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    Semaglutide injection

    Semaglutide:0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg

    Drug: Semaglutide

  • Active comparator
    Wegovy®

    Wegovy®:0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg

    Drug: Semaglutide

Interventions

  • The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.

  • The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.

06

What researchers measure

Primary outcomes

  1. Change in body weight

    Percent

    Time frame: From baseline at week 0 to week 44

Secondary outcomes

  1. Change in body weight

    Percent

    Time frame: From baseline at week 0 to week 28

  2. Subjects who achieve body weight reduction equal to or above 5%

    Number of subjects

    Time frame: From baseline at week 0 to week 44

  3. Subjects who achieve body weight reduction equal to or above 10%

    Number of subjects

    Time frame: From baseline at week 0 to week 44

  4. Subjects who achieve body weight reduction equal to or above 15%

    Number of subjects

    Time frame: From baseline at week 0 to week 44

  5. Change in body mass index (BMI)

    kg/m\^2

    Time frame: From baseline at week 0 to week 44

  6. Change in waist circumference

    cm

    Time frame: From baseline at week 0 to week 44

  7. Change in systolic blood pressure and diastolic blood pressure

    mmHg

    Time frame: From baseline at week 0 to week 44

  8. Change in lipids

    mg/dL

    Time frame: From baseline at week 0 to week 44

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for May 2026, 19 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartEst.
Oct 30, 2024
Primary completionEst.
May 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06633783
Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Oct 30, 2024 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 9, 2024

Study contacts

xiaoying Li, Doctor
Contact
xiaoying_li@hotmail.com
0086-021-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion